Efficacy of High-Intensity Focused Ultrasound Combined With GnRH-a for Adenomyosis: A Systematic Review and Meta-Analysis - PubMed
- ️Fri Jan 01 2021
Meta-Analysis
Efficacy of High-Intensity Focused Ultrasound Combined With GnRH-a for Adenomyosis: A Systematic Review and Meta-Analysis
Li-Li Pang et al. Front Public Health. 2021.
Abstract
Objective: High-intensity focused ultrasound (HIFU) is an innovative non-invasive technology used for adenomyosis. Gonadotropin-releasing hormone agonist (GnRH-a) is a hormone commonly used for adenomyosis. We investigated and assessed the efficacy of HIFU combined with GnRH-a for adenomyosis. Methods: For this systematic review and meta-analysis, we searched Pubmed, Cochrane Library, Web of Science, Embase, CNKI, WanFang, and VIP databases for relevant articles published in Chinese or English that compared HIFU combined with GnRH-a vs. HIFU alone in patients with adenomyosis. The last literature search was completed on January 31, 2021. Two reviewers independently assessed study eligibility and assessed risk of bias. Another two reviewers extracted the data. The RevMan5.3 software was used for the data analysis. Changes in volume of the uterine and adenomyotic lesion were defined as the primary outcomes. The secondary outcomes were visual analog scale (VAS) scores for dysmenorrhea, menstrual volume scores, serum CA125 levels, and recurrence rate. This study is registered with PROSPERO (CRD42021234301). Results: Three hundred and ninety potentially relevant articles were screened. Nine studies with data for 766 patients were finally included. Compared with the HIFU alone group, the HIFU combined with GnRH-a group had a higher rate of uterine volume reduction (MD 7.51, 95% CI 5.84-9.17, p < 0.00001), smaller adenomyotic lesion volume (MD 4.11, 95% CI 2.93-5.30, p < 0.00001), lower VAS score for dysmenorrhea (MD 1.27, 95% CI 0.54-2.01, p = 0.0007) and menstrual volume score (MD 0.88, 95% CI 0.73-1.04, p < 0.00001), and lower CA125 level (SMD 0.31, 95% CI 0.05-0.56, p = 0.02) after the procedure. The recurrence rate in the HIFU combined with GnRH-a group was lower than that in the HIFU alone group (RR 0.28, 95% CI 0.10-0.82, p = 0.02). Conclusions: Compared with HIFU treatment alone, HIFU combined with GnRH-a for the treatment of adenomyosis has greater efficacy in decreasing the volumes of the uterine and adenomyotic lesions and alleviating symptoms. However, since the number of the included studies was too small and most of them were written in Chinese, this conclusion needs to be referenced with caution. And the long-term evidence of its efficacy is still insufficient. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ identifier [CRD42021234].
Keywords: GnRH-a; adenomyosis; gonadotropin-releasing hormone agonist; high-intensity focused ultrasound; meta-analysis.
Copyright © 2021 Pang, Mei, Fan, Zhao, Li and Wen.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Flow diagram showing selection of articles for this systematic review.

Review authors' judgements about each risk of bias item for each of included study.

Review authors' judgements about each risk of bias item presented as percentages across all included study.

Meta-analysis of uterine volume changes in two groups.

Meta-analysis of lesion volume changes in two groups.

Meta-analysis of visual analog scale (VAS) scores of dysmenorrhea in two groups.

Sensitivity analysis of visual analog scale (VAS) scores of dysmenorrhea in two groups.

Meta-analysis of menstrual volume scores in two groups.

Meta-analysis of serum CA-125 levels in two groups.

Meta-analysis of recurrence rate in two groups.
Similar articles
-
Zhao TT, Pang LL, Yang LL, Li RN, Fan LX, Wen Y. Zhao TT, et al. Arch Gynecol Obstet. 2023 Aug;308(2):351-362. doi: 10.1007/s00404-022-06720-z. Epub 2022 Aug 10. Arch Gynecol Obstet. 2023. PMID: 35947146 Review.
-
Guo Y, Duan H, Cheng J, Zhang Y. Guo Y, et al. BJOG. 2017 Aug;124 Suppl 3:7-11. doi: 10.1111/1471-0528.14736. BJOG. 2017. PMID: 28856862
-
Ye MZ, Deng XL, Zhu XG, Xue M. Ye MZ, et al. Zhonghua Fu Chan Ke Za Zhi. 2016 Sep 25;51(9):643-649. doi: 10.3760/cma.j.issn.0529-567X.2016.09.002. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27671043 Chinese.
-
Otgontuya A, Jeng CJ, Wu TN, Chuang LT, Shen J. Otgontuya A, et al. Taiwan J Obstet Gynecol. 2023 Mar;62(2):226-238. doi: 10.1016/j.tjog.2022.11.009. Taiwan J Obstet Gynecol. 2023. PMID: 36965889 Review.
Cited by
-
Athanasiou A, Fruscalzo A, Dedes I, Mueller MD, Londero AP, Marti C, Guani B, Feki A. Athanasiou A, et al. J Clin Med. 2024 Sep 29;13(19):5828. doi: 10.3390/jcm13195828. J Clin Med. 2024. PMID: 39407887 Free PMC article. Review.
-
Chu Z, Jia L, Dai J, Wu Q, Tian F, Bai S. Chu Z, et al. J Ovarian Res. 2024 Jan 12;17(1):16. doi: 10.1186/s13048-023-01320-0. J Ovarian Res. 2024. PMID: 38216945 Free PMC article.
-
Analysis of related factors influencing postoperative recurrence of adenomyosis treated with HIFU.
Fan LX, Zhang Y, Yang LL, Ji XL, Wang Y, Huang YF, Shi L, Wen Y. Fan LX, et al. Arch Gynecol Obstet. 2024 May;309(5):1765-1773. doi: 10.1007/s00404-023-07340-x. Epub 2024 Feb 12. Arch Gynecol Obstet. 2024. PMID: 38347252 Review.
-
Zhang G, Li L, Sun M, Yu X. Zhang G, et al. Reprod Sci. 2025 Jan;32(1):15-25. doi: 10.1007/s43032-024-01745-y. Epub 2024 Nov 12. Reprod Sci. 2025. PMID: 39532767 Free PMC article. Review.
-
Qin Z, Dong Z, Tang H, Zhang S, Wang H, Bao M, Wei W, Shi R, Chen J, Xia B. Qin Z, et al. Front Surg. 2022 Aug 18;9:914725. doi: 10.3389/fsurg.2022.914725. eCollection 2022. Front Surg. 2022. PMID: 36061067 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous